Blockchain Registration Transaction Record

VERAXA Biotech and Ardigen Partner to Boost BiTAC Pipeline with AI

VERAXA Biotech (VRXA) partners with AI firm Ardigen to enhance its BiTAC T-cell engager pipeline, using machine learning to improve tumor targeting and reduce toxicity in precision oncology.

This collaboration matters because it applies artificial intelligence to tackle one of the biggest challenges in oncology: developing therapies that kill tumors without harming healthy tissues. By using AI to analyze clinical data from failed trials, VERAXA could identify safer, more effective dual-target combinations, potentially increasing the success rate of cancer treatments and bringing new options to patients faster.